Skip to main content
main-content

The independent medical news service

17-08-2021 | Oncology | News | Article

FDA approves HIF-2α inhibitor belzutifan for VHL-associated tumors

Read more on this US FDA announcement here

16-08-2021 | Oncology | News | Article

Lenvatinib–pembrolizumab gets FDA nod for first-line advanced RCC

Click through for the details of this decision

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

21-06-2021 | Oncology | News | Article

Bacterial product linked to improved metastatic RCC response to nivolumab plus ipilimumab

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

09-06-2021 | Oncology | News | Article

HRQoL data favor lenvatinib–pembrolizumab over sunitinib in advanced RCC

Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

07-06-2021 | Oncology | News | Article

CANTATA: No improvement in advanced RCC outcomes with telaglenastat addition

The combination of telaglenastat and cabozantinib offers no extra benefit over cabozantinib alone in the second- or third-line treatment of advanced clear cell renal cell carcinoma, suggest phase 2 trial results.